Related Experiment Video
Updated: Jun 25, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations
Anastasia Ivanova1, Michael Murphy
1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7420, USA. aivanova@bios.unc.edu
Abstract:
The primary objective of the dose-escalation trial for NGX267 was to estimate the maximally tolerated dose (MTD) and to gather detailed clinical and pharmacokinetic observations near the MTD. The MTD was defined based on the weighted average of moderate and severe adverse events. An adaptive design was employed to concentrate dosage assignments at or near the MTD. Favoring the acquisition of data near the MTD, at the expense of information at lower dosage levels, resulted in a shorter trial and no loss of the type of information required to inform subsequent studies where larger normal volunteer or patient samples are evaluated.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimen: Individualization
Dosage Regimens: Designs and Approaches
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients